Inflammation Measured in the ER Tracks With PTSD Symptoms for Six Months, AURORA Study Finds

On May 8, researchers with the AURORA Study published a paper in Psychological Medicine that asks a simple question. Can blood drawn in the emergency department after a traumatic event say anything about PTSD symptoms in the months that follow?

The team analyzed blood samples from 742 adults who came to one of 29 U.S. emergency departments within 72 hours of a traumatic event. About three in four had been in a motor vehicle collision. Researchers measured five inflammatory signaling proteins called cytokines, then tracked each person's PTSD symptoms on the PCL-5 at two weeks, eight weeks, three months, and six months. People with higher inflammation in the emergency department reported higher PTSD symptoms throughout those six months. The link held after the team accounted for age, income, trauma type, pain, prior trauma, and earlier mental health history.

What did the AURORA study find about inflammation and PTSD?

The AURORA study found that inflammation measured within days of trauma was associated with PTSD symptom severity for the next six months. The association was small, and it stayed steady from the first check-in to the last.

The pattern differed by sex. Among men, a combined index of four pro-inflammatory markers (IL-6, IL-8, TNF-alpha, and IFN-gamma) was associated with higher symptoms, as were IL-6, IL-8, and TNF-alpha on their own. Among women, the only marker associated with higher symptoms was IL-10, which usually acts to calm inflammation. The authors point to hormonal differences as one possible explanation and call for more research.

The need is plain in the study's own numbers. Two weeks after the emergency visit, 42.7 percent of participants scored above the threshold for probable PTSD. At six months, 33.2 percent still did.

Why does a blood signal matter after trauma?

A blood signal matters because most people learn they are at risk for PTSD only after symptoms have taken hold. The authors write that inflammation levels could feasibly be collected in the emergency department and added to prediction models that identify who is at highest risk, so early support can reach those people first.

John Schmitt, co-founder and CEO of iXpressGenes (iXG), shared the study on LinkedIn this week.

"We've known it. We've been saying it. We can measure it. And now the world is finally catching up," Schmitt said.

Schmitt is a 20-year Army veteran. iXpressGenes is a veteran-led molecular diagnostics company in Huntsville, Alabama, and the laboratory partner for Neurova Labs.

The researchers are careful about what the finding means, and so are we. It is an association in one group of emergency department patients, the effects were small, and an earlier emergency department study pointed the other way for men. The authors say more work is needed to test cause and effect. The direction is still worth noting.

How does Neurova Labs measure biology?

Neurova Labs measures biology with an optional 22-marker panel that reads RNA gene expression from whole blood, run through iXpressGenes, a CLIA-certified, CAP-accredited laboratory. It is a different method from the protein analysis in the AURORA study, and we see the two lines of research as complementary. Several of the signals AURORA tracked, including IL-6, TNF-alpha, and IFN-gamma, are also on our panel.

In a 2026 Neurova Labs observational cohort of 103 members, measured at Day 1, Day 5, and Day 30, members who entered with the highest inflammatory burden showed the largest changes. Among the top 25 percent at Day 1 (26 members), the Global Inflammation Score, a 0 to 100 composite from the panel, fell 48 percent by Day 30, with 23 of 26 improving. In our 2026 community cohort studies with the YMCA of Orange County, participants reported a 28 percent improvement in trauma symptom scores on the PCL-5 and a 24 percent improvement in psychological distress on the Kessler-6.

We describe these as observational findings, and a controlled validation study is underway.

Why did Neurova Labs build Neurova Academy?

Neurova Labs first built its technology for veterans living with PTSD. That origin is why research like AURORA matters to us. We want a future where a service member, a firefighter, or a Y member can train their brain and see objective signs of how they are responding. Studies like this one move that future closer, and we are grateful to the researchers and to the trauma survivors who took part.

If you or someone you know is struggling, call or text 988 and press 1 to reach the Veterans Crisis Line.

To bring Neurova Academy to your unit, clinic, or community, visit neurovalabs.com.

About Neurova Labs

Neurova Labs is a veteran-led neurotechnology company based in Salt Lake City. Its program, Neurova Academy, is a facilitator-led neuro-immersive brain training program designed to support focus, stress regulation, and mental endurance, with no clinical infrastructure required. Programs can add an optional 22-marker panel measuring RNA gene expression from whole blood, processed by iXpressGenes, a CLIA-certified, CAP-accredited laboratory. Neurova Labs works with military units, first responder agencies, clinics, and community organizations. Learn more at neurovalabs.com.

Neurova Academy is a general wellness and cognitive training program. It is not a medical device and is not offered to diagnose, treat, cure, or mitigate any disease or condition, including concussion, traumatic brain injury, or CTE. References to news reporting, government publications, and published research are for commentary only and do not imply endorsement of Neurova Labs by any federal entity or research institution.